JP2021533770A5 - - Google Patents
Info
- Publication number
- JP2021533770A5 JP2021533770A5 JP2021507628A JP2021507628A JP2021533770A5 JP 2021533770 A5 JP2021533770 A5 JP 2021533770A5 JP 2021507628 A JP2021507628 A JP 2021507628A JP 2021507628 A JP2021507628 A JP 2021507628A JP 2021533770 A5 JP2021533770 A5 JP 2021533770A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- chain variable
- variable region
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810920403.6 | 2018-08-14 | ||
| CN201810920403.6A CN110818793A (zh) | 2018-08-14 | 2018-08-14 | 抗IL-1β的抗体、其药物组合物及其用途 |
| PCT/CN2019/100343 WO2020034941A1 (zh) | 2018-08-14 | 2019-08-13 | 抗IL-1β的抗体、其药物组合物及其用途 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533770A JP2021533770A (ja) | 2021-12-09 |
| JPWO2020034941A5 JPWO2020034941A5 (https=) | 2022-08-09 |
| JP2021533770A5 true JP2021533770A5 (https=) | 2022-08-09 |
| JP7576022B2 JP7576022B2 (ja) | 2024-10-30 |
Family
ID=69524699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507628A Active JP7576022B2 (ja) | 2018-08-14 | 2019-08-13 | 抗ＩＬ－１β抗体およびその医薬組成物およびそれらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12286473B2 (https=) |
| EP (1) | EP3845560A4 (https=) |
| JP (1) | JP7576022B2 (https=) |
| KR (1) | KR20210046024A (https=) |
| CN (2) | CN110818793A (https=) |
| AU (1) | AU2019320927B2 (https=) |
| BR (1) | BR112021002794A2 (https=) |
| CA (1) | CA3108414A1 (https=) |
| EA (1) | EA202190518A1 (https=) |
| IL (1) | IL280596B2 (https=) |
| MX (2) | MX2021001778A (https=) |
| MY (1) | MY209465A (https=) |
| PH (1) | PH12021550298A1 (https=) |
| SG (1) | SG11202101435XA (https=) |
| WO (1) | WO2020034941A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN113444177A (zh) * | 2020-03-27 | 2021-09-28 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| BR112022022089A2 (pt) * | 2020-05-22 | 2022-12-13 | R Pharm Overseas Inc | Composição de proteína heterodimérica, composição terapêutica que compreende a mesma e uso da dita composição para tratar uma doença associada à modulação de il-1ss |
| WO2021257539A1 (en) * | 2020-06-16 | 2021-12-23 | Academia Sinica | ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF |
| CN116063488B (zh) * | 2022-10-21 | 2025-09-30 | 杭州靶向食品科技有限公司 | 一种单克隆抗体及其治疗痛风的用途 |
| CN116688130A (zh) * | 2023-06-08 | 2023-09-05 | 桂林医学院附属医院 | 靶向IL-1β/IL-1R1通路的拮抗剂在抑制肝癌肺转移前微环境或肺转移的药物中的应用 |
| KR102844307B1 (ko) | 2023-09-26 | 2025-08-07 | 사회복지법인 삼성생명공익재단 | 비흡연자의 조기 폐암 진단용 바이오마커 및 이의 용도 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| CA2824167C (en) * | 2002-09-06 | 2018-09-25 | Amgen Inc. | Therapeutic human anti-il-1r1 monoclonal antibody |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| DK1899378T3 (da) * | 2005-06-21 | 2010-02-01 | Xoma Technology Ltd | IL-1 beta-bindende antistoffer og fragmenter deraf |
| EP2468301A1 (en) | 2007-05-29 | 2012-06-27 | Novartis AG | New indications for anti-IL-1-beta therapy |
| IN2012DN02634A (https=) | 2009-10-15 | 2015-09-04 | Abbvie Inc | |
| JP5866130B2 (ja) * | 2010-09-10 | 2016-02-17 | アペクシジェン， インコーポレイテッド | 抗ＩＬ−１β抗体およびその使用方法 |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| JP5918275B2 (ja) | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
| CA2888583C (en) | 2012-11-05 | 2022-03-29 | Delenex Therapeutics Ag | Binding members to il-1 beta |
| CN105324396A (zh) * | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| CN103554264B (zh) * | 2013-11-05 | 2015-08-12 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL-1β和IL-17A的双特异性抗体及其应用 |
| AU2015345323A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| CN107474139B (zh) * | 2017-06-23 | 2021-04-27 | 苏州博聚华生物医药科技有限公司 | 一种靶向人肿瘤干细胞的单克隆抗体及其应用 |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN113444177A (zh) * | 2020-03-27 | 2021-09-28 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
-
2018
- 2018-08-14 CN CN201810920403.6A patent/CN110818793A/zh active Pending
-
2019
- 2019-08-13 WO PCT/CN2019/100343 patent/WO2020034941A1/zh not_active Ceased
- 2019-08-13 BR BR112021002794-7A patent/BR112021002794A2/pt unknown
- 2019-08-13 IL IL280596A patent/IL280596B2/en unknown
- 2019-08-13 MY MYPI2021000751A patent/MY209465A/en unknown
- 2019-08-13 EP EP19849700.0A patent/EP3845560A4/en active Pending
- 2019-08-13 EA EA202190518A patent/EA202190518A1/ru unknown
- 2019-08-13 CN CN201980053246.6A patent/CN112654640B/zh active Active
- 2019-08-13 JP JP2021507628A patent/JP7576022B2/ja active Active
- 2019-08-13 KR KR1020217007489A patent/KR20210046024A/ko active Pending
- 2019-08-13 SG SG11202101435XA patent/SG11202101435XA/en unknown
- 2019-08-13 US US17/267,115 patent/US12286473B2/en active Active
- 2019-08-13 MX MX2021001778A patent/MX2021001778A/es unknown
- 2019-08-13 CA CA3108414A patent/CA3108414A1/en active Pending
- 2019-08-13 AU AU2019320927A patent/AU2019320927B2/en active Active
-
2021
- 2021-02-10 PH PH12021550298A patent/PH12021550298A1/en unknown
- 2021-02-12 MX MX2025005169A patent/MX2025005169A/es unknown
-
2025
- 2025-03-26 US US19/090,745 patent/US20260035455A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533770A5 (https=) | ||
| JP7273101B2 (ja) | Ｃｄ３８に結合する抗体治療剤 | |
| CN108290948B (zh) | 抗-cd47抗体及使用方法 | |
| CN112969714B (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| KR20180006369A (ko) | Cd47에 결합하는 항체 치료제 | |
| CN114729053B (zh) | 一种4-1bb结合蛋白及其应用 | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| CN115785268B (zh) | 抗cd47抗体及其用途 | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| KR20150063311A (ko) | Il-6 결합 분자 | |
| KR20220119389A (ko) | 분리된 항원 axl 결합 단백질 및 그의 용도 | |
| KR20250067124A (ko) | 이중특이성 항-c-kit 및 항-cd203c 항원 결합 분자 및 이의 용도 | |
| KR20220110753A (ko) | 항-bcma/항-4-1bb 이중특이성 항체 및 그의 용도 | |
| KR20240135654A (ko) | 항-her2/trop2 항체 및 이의 용도 | |
| JPWO2020034941A5 (https=) | ||
| JP7036471B2 (ja) | デスレセプター４及びデスレセプター５に結合する非常に強力な抗体 | |
| JPWO2020108611A5 (https=) | ||
| AU2019388931A1 (en) | CD40 antibody pharmaceutical composition and use thereof | |
| KR20180010178A (ko) | Jag1에 결합하는 항체 치료제 | |
| KR20240123800A (ko) | 항tnfr2 항체 및 이의 용도 | |
| CN111303288B (zh) | 一种分离的结合抗原psma的蛋白及其用途 | |
| CA3221903A1 (en) | Anti-upar antibodies and uses thereof |